BioPharmSignal logoBioPharmSignal

Biotech News

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

Rocket Pharmaceuticals (RCKT)Rocket PharmaceuticalsEarnings

PRV monetization provides $180 million in non-dilutive capital to support cardiovascular pipeline Cash runway extended into the second quarter of 2028 CRANBURY, N.J. --(BUSINESS WIRE)--Apr. 28, 2026-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology

Open original release

Related news

RCKTRocket Pharmaceuticals2026-05-07 20:00 EST

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

ARWRArrowhead Pharmaceuticals2026-07-21 11:30 EST

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results

CRNXCrinetics Pharmaceuticals2026-06-30 20:05 EST

Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026

CRNXCrinetics Pharmaceuticals2026-05-07 20:05 EST

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

ARWRArrowhead Pharmaceuticals2026-05-07 20:01 EST

Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results

ZNTLZentalis2026-05-12 20:05 EST

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

RIGLRigel Pharmaceuticals2026-07-28 12:05 EST

Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results

BCRXBioCryst Pharmaceuticals2026-07-22 11:00 EST

BioCryst to Report Second Quarter 2026 Financial Results on August 5

GERNGeron2026-07-22 11:00 EST

Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026

BCRXBioCryst Pharmaceuticals2026-05-06 11:00 EST

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

View all latest news

Rocket Pharmaceuticals

Rocket Pharmaceuticals is a gene-therapy company focused on rare pediatric and hematologic diseases. Its story is built around using advanced genetic medicine to address severe inherited conditions.

Recent company news

RCKTRocket Pharmaceuticals2026-05-07 20:00 EST

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

RCKTRocket Pharmaceuticals2026-04-28 11:00 EST

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

RCKTRocket Pharmaceuticals2026-03-27 11:00 EST

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

RCKTRocket Pharmaceuticals2026-02-26 21:00 EST

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

RCKTRocket Pharmaceuticals2026-02-23 12:00 EST

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Stock data

Close
3.25 USD
Market cap
315.57M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States